CRISPR Gene Editing Therapies Advance in Clinical Development
Companies including Intellia Therapeutics, Locus Biosciences, and CRISPR Therapeutics are progressing next-generation gene-editing medicines. Advances focus on precision modification and novel delivery platforms for genetic therapies.
The development of CRISPR-based gene editing therapies, a new class of medicines designed to precisely modify disease-causing DNA sequences, is advancing with companies such as Intellia Therapeutics, Locus Biosciences, and CRISPR Therapeutics leading the way. These therapies utilize CRISPR technology to edit DNA or regulate gene expression.
Intellia Therapeutics has the most advanced candidate, lonvoguran ziclumeran (NTLA-2002), approaching registration for hereditary angioedema (HAE). The company initiated a rolling submission to the U.S. Food and Drug Administration (FDA) in 2026, based on positive Phase III results. This therapy is designed as a one-time treatment to provide durable prevention of HAE attacks.
CRISPR Therapeutics is evaluating CTX310, an in vivo therapy targeting the ANGPTL3 gene for refractory dyslipidemias. This therapy is currently in a first-in-human Phase I trial. Concurrently, Locus Biosciences is investigating its CRISPR-Cas3-enhanced bacteriophage therapy, LBP-EC01, for drug-resistant E. coli urinary tract infections in an ongoing Phase II trial.
Progress in CRISPR technology is driven by improvements in editing precision, delivery systems, and the development of next-generation editors like base and prime editing. These methods enable targeted genetic modifications without causing double-strand DNA breaks, potentially enhancing safety and accuracy.
Overall, over 20 companies are evaluating more than 30 CRISPR therapy candidates across various stages of development. These therapies hold potential for treating a range of conditions, including genetic, hematologic, oncologic, and neurological disorders.